Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 84 Operating Margin % is 11.80% as of Dec. 2025, which is 4% below its 10-year median of 12.25. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, TSH Biopharm ranks better than 74.4% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. TSH Biopharm's Operating Income for the
three
months ended in Dec. 2025 was NT$42 Mil. TSH Biopharm's Revenue for the
three
months ended in Dec. 2025 was NT$358 Mil. Therefore, TSH Biopharm's Operating Margin % for the quarter that ended in Dec. 2025 was 11.80%.
Good Sign:
TSH Biopharm Corp Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for TSH Biopharm's Operating Margin % or its related term are showing as below:
ROCO:8432'
s Operating Margin % Range Over the Past 10 Years
Min: 6.26 Med: 12.25 Max: 16.57
Current: 16.41
ROCO:8432's Operating Margin % is ranked better than 74.4% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.57
vs ROCO:8432: 16.41
TSH Biopharm's 5-Year Average Operating Margin % Growth Rate was 0.40% per year.
TSH Biopharm's Operating Income for the
three
months ended in Dec. 2025 was NT$42 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$219 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
TSH Biopharm Operating Margin % Related Terms
TSH Biopharm Operating Margin % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8432 vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Operating Margin % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
TSH Biopharm's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a Operating Margin % of 11.80% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on TSH Biopharm and its competitors. This is near median its historical median of 12.25. Over the past decade, TSH Biopharm's Operating Margin % has ranged from 6.26 to 16.57. According to the industry distribution chart, TSH Biopharm ranks #246 out of 961 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is TSH Biopharm's Operating Margin % too high?
TSH Biopharm's current Operating Margin % of 11.80% is near median its 10-year median of 12.25. Over the past 10 years, this metric has ranged from a low of 6.26 to a high of 16.57. The Drug Manufacturers industry median Operating Margin % is 7.57. TSH Biopharm's value of 11.80% is 55.9% above this industry median. Based on the distribution chart, TSH Biopharm ranks #246 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #246 out of 961 companies for Operating Margin %. This puts TSH Biopharm in the upper half of its industry. The industry median Operating Margin % is 7.57. TSH Biopharm's value of 11.80% is 55.9% above this benchmark. Historically, TSH Biopharm's own Operating Margin % has ranged from 6.26 to 16.57 over the past decade. While the company's 10-year median is 12.25 vs. the industry median of 7.57, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Operating Margin % of 11.80% is 55.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Operating Margin % is 11.80%, which is near median its own 10-year median of 12.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current Operating Margin % is 11.80%, which is near median its 10-year median of 12.25 and 55.9% above the Drug Manufacturers industry median of 7.57. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Operating Margin % is 11.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
Operating Margin %: 11.80% (near median its 10-year median of 12.25)
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
Industry Position: 55.9% above the Drug Manufacturers median (#246 of 961)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
